
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics Inc. is focused on developing its topical eye drop treatment, aceclidine, for presbyopia, demonstrating significant patient benefits in trials, with 84% of participants achieving at least a 4-line gain in near vision. The probability-adjusted revenue projections indicate a substantial growth trajectory, moving from an anticipated $7.2 million in 2025 to approximately $421.2 million by 2034, highlighting the market potential for aceclidine in treating presbyopia. Notably, aceclidine's selective targeting of the iris sphincter muscle while avoiding myopic shifts positions it as a promising therapy with durable efficacy and rapid visual improvements.
Bears say
LENZ Therapeutics Inc reported a significant net loss of $10.3 million, or $0.40 per share, for the second quarter of 2024, highlighting the company's ongoing financial challenges. The investment outlook is further dampened by the potential failure of its developmental candidates to meet peak commercial revenue estimates, alongside concerns about the ability to secure necessary capital resources and the continued viability of program development. Additionally, complications associated with existing treatment options, such as pilocarpine, suggest market penetration obstacles and could hinder the company's growth in the ophthalmic pharmaceutical sector.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares